Amarin Corp Plc (AMRN)

[ziploc_1]

JR...QUOTE..."The co-administration of PUFAs (e.g. LrEtEPA) with additives including phospholipids and/or additional emulsifiers facilitates in viva absorption of the fatty acid in the form of phospholipid conjugate. Not only is such compound primed for uptake by cells because phospholipids are a major component of cell membrane, but it is also expected to have a higher efficiency as crossing the blood-brain barrier (BBB), thereby delivering the fatty acid which is the active ingredient of the composition to the brain. The BBB can be a roadblock for pharmaceutical agents to access their therapeutic target in the brain or reach a sufficient level inside the brain. Therefore, the lymph releasing formulation of the present technology may provide a novel strategy and platform for delivering fatty acids across the BBB for them to exert their anti-inflammatory, pro-cognitive, and/or other neuroprotective effects useful in the treatment of a variety of neurological diseases and disorders"

This IMO is grounds for believing that Lr-Et-EPA has a positive effect in slowing of Alzheimers.